Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer

BACKGROUND: Immunotherapies targeting the PD-1 checkpoint pathway have recently gained regulatory approval in numerous cancer types. With the widespread use of immune checkpoint therapies, varying patterns of responses and immune-related adverse events are being observed. CASE PRESENTATION: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweis, Randy F., Zha, Yuanyuan, Pass, Lomax, Heiss, Brian, Chongsuwat, Tara, Luke, Jason J., Gajewski, Thomas F., Szmulewitz, Russell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883337/
https://www.ncbi.nlm.nih.gov/pubmed/29618376
http://dx.doi.org/10.1186/s40425-018-0334-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883337/
https://www.ncbi.nlm.nih.gov/pubmed/29618376
http://dx.doi.org/10.1186/s40425-018-0334-x

Ejemplares similares